Pazopanib, an investigational topical therapy for wet macular degeneration, shows positive beneficial results in clinical studies, Says Dr. Ilan Cohen, a New York City Ophthalmologist.
There are currently two drugs available for the treatment of Macular Degeneration: Lucentis, and Avastin. These drugs have been found effective both in preventing the progression of the disease and in improving overall visual acuity; however, both of these medications need to be injected into the eye with a needle every month, indefinitely, in order to prevent progression of the disease. In addition to the pain and the discomfort of receiving an injection into the eye each month, the patients are also exposed to the risk of a catastrophic eye infection due to a needle penetrating the eye. Moreover, the very high cost of the medication along with its administration by an Ophthalmologist can become a large burden on the healthcare budget and patients without insurance may not be able to afford it.
Pazopanib, on the other hand, can be administered as topical eye drops. The active molecule in Pazopanib works to prevent irregular blood vessels and subsequent bleeding under the macula. If this medication is proven effective in subsequent clinical studies and is approved by the FDA, patients with macular degeneration may be relieved of the nightmare of receiving monthly eye injections.